280 related articles for article (PubMed ID: 28705064)
21. Accuracy and Interobserver Agreement for Prostate Imaging Reporting and Data System, Version 2, for the Characterization of Lesions Identified on Multiparametric MRI of the Prostate.
Purysko AS; Bittencourt LK; Bullen JA; Mostardeiro TR; Herts BR; Klein EA
AJR Am J Roentgenol; 2017 Aug; 209(2):339-349. PubMed ID: 28570099
[TBL] [Abstract][Full Text] [Related]
22. Predictive clinical features for negative histopathology of MRI/Ultrasound-fusion-guided prostate biopsy in patients with high likelihood of cancer at prostate MRI: Analysis from a urologic outpatient clinic1.
Apfelbeck M; Pfitzinger P; Bischoff R; Rath L; Buchner A; Mumm JN; Schlenker B; Stief CG; Chaloupka M; Clevert DA
Clin Hemorheol Microcirc; 2020; 76(4):503-511. PubMed ID: 33337358
[TBL] [Abstract][Full Text] [Related]
23. Use of the Prostate Imaging Reporting and Data System (PI-RADS) for Prostate Cancer Detection with Multiparametric Magnetic Resonance Imaging: A Diagnostic Meta-analysis.
Hamoen EHJ; de Rooij M; Witjes JA; Barentsz JO; Rovers MM
Eur Urol; 2015 Jun; 67(6):1112-1121. PubMed ID: 25466942
[TBL] [Abstract][Full Text] [Related]
24. The use of 29 MHz transrectal micro-ultrasound to stratify the prostate cancer risk in patients with PI-RADS III lesions at multiparametric MRI: A single institutional analysis.
Avolio PP; Lughezzani G; Paciotti M; Maffei D; Uleri A; Frego N; Hurle R; Lazzeri M; Saita A; Guazzoni G; Casale P; Buffi NM
Urol Oncol; 2021 Dec; 39(12):832.e1-832.e7. PubMed ID: 34183255
[TBL] [Abstract][Full Text] [Related]
25. Does the Prostate Imaging-Reporting and Data System (PI-RADS) version 2 improve accuracy in reporting anterior lesions on multiparametric magnetic resonance imaging (mpMRI)?
Hoffmann R; Logan C; O'Callaghan M; Gormly K; Chan K; Foreman D
Int Urol Nephrol; 2018 Jan; 50(1):13-19. PubMed ID: 29188489
[TBL] [Abstract][Full Text] [Related]
26. High prostate cancer gene 3 (PCA3) scores are associated with elevated Prostate Imaging Reporting and Data System (PI-RADS) grade and biopsy Gleason score, at magnetic resonance imaging/ultrasonography fusion software-based targeted prostate biopsy after a previous negative standard biopsy.
De Luca S; Passera R; Cattaneo G; Manfredi M; Mele F; Fiori C; Bollito E; Cirillo S; Porpiglia F
BJU Int; 2016 Nov; 118(5):723-730. PubMed ID: 27112799
[TBL] [Abstract][Full Text] [Related]
27. Validation of Prostate Imaging-Reporting and Data System Version 2: A Retrospective Analysis.
Nguyentat M; Ushinsky A; Miranda-Aguirre A; Uchio E; Lall C; Shirkhoda L; Lee T; Green C; Houshyar R
Curr Probl Diagn Radiol; 2018 Nov; 47(6):404-409. PubMed ID: 29126575
[TBL] [Abstract][Full Text] [Related]
28. Diagnostic accuracy of magnetic resonance imaging (MRI) prostate imaging reporting and data system (PI-RADS) scoring in a transperineal prostate biopsy setting.
Grey AD; Chana MS; Popert R; Wolfe K; Liyanage SH; Acher PL
BJU Int; 2015 May; 115(5):728-35. PubMed ID: 25041307
[TBL] [Abstract][Full Text] [Related]
29. Value of 3-T multiparametric magnetic resonance imaging and magnetic resonance-guided biopsy for early risk restratification in active surveillance of low-risk prostate cancer: a prospective multicenter cohort study.
Hoeks CM; Somford DM; van Oort IM; Vergunst H; Oddens JR; Smits GA; Roobol MJ; Bul M; Hambrock T; Witjes JA; Fütterer JJ; Hulsbergen-van de Kaa CA; Barentsz JO
Invest Radiol; 2014 Mar; 49(3):165-72. PubMed ID: 24220253
[TBL] [Abstract][Full Text] [Related]
30. Multiparametric magnetic resonance imaging guided diagnostic biopsy detects significant prostate cancer and could reduce unnecessary biopsies and over detection: a prospective study.
Thompson JE; Moses D; Shnier R; Brenner P; Delprado W; Ponsky L; Pulbrook M; Böhm M; Haynes AM; Hayen A; Stricker PD
J Urol; 2014 Jul; 192(1):67-74. PubMed ID: 24518762
[TBL] [Abstract][Full Text] [Related]
31. Prostate cancer gene 3 (PCA3) is of additional predictive value in patients with PI-RADS grade III (intermediate) lesions in the MR-guided re-biopsy setting for prostate cancer.
Kaufmann S; Bedke J; Gatidis S; Hennenlotter J; Kramer U; Notohamiprodjo M; Nikolaou K; Stenzl A; Kruck S
World J Urol; 2016 Apr; 34(4):509-15. PubMed ID: 26267808
[TBL] [Abstract][Full Text] [Related]
32. Combination of prostate imaging reporting and data system (PI-RADS) score and prostate-specific antigen (PSA) density predicts biopsy outcome in prostate biopsy naïve patients.
Washino S; Okochi T; Saito K; Konishi T; Hirai M; Kobayashi Y; Miyagawa T
BJU Int; 2017 Feb; 119(2):225-233. PubMed ID: 26935594
[TBL] [Abstract][Full Text] [Related]
33. Evaluating the efficacy of a low-cost cognitive MRI-targeted prostate biopsy protocol: is there still a role for lower volume centers in the Prostate Imaging Reporting and Data System (PI-RADS) version 2 era?
Takeshima Y; Tanaka Y; Takemura K; Nakazono S; Yamashita E; Kume H
Int Urol Nephrol; 2020 Nov; 52(11):2043-2050. PubMed ID: 32705477
[TBL] [Abstract][Full Text] [Related]
34. Prostate Imaging Reporting and Data System and Likert Scoring System: Multiparametric MR Imaging Validation Study to Screen Patients for Initial Biopsy.
Renard-Penna R; Mozer P; Cornud F; Barry-Delongchamps N; Bruguière E; Portalez D; Malavaud B
Radiology; 2015 May; 275(2):458-68. PubMed ID: 25599415
[TBL] [Abstract][Full Text] [Related]
35. Added Value of Multiparametric Ultrasonography in Magnetic Resonance Imaging and Ultrasonography Fusion-guided Biopsy of the Prostate in Patients With Suspicion for Prostate Cancer.
Maxeiner A; Stephan C; Durmus T; Slowinski T; Cash H; Fischer T
Urology; 2015 Jul; 86(1):108-14. PubMed ID: 26142593
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of the prostate imaging reporting and data system for the detection of prostate cancer by the results of targeted biopsy of the prostate.
Baur AD; Maxeiner A; Franiel T; Kilic E; Huppertz A; Schwenke C; Hamm B; Durmus T
Invest Radiol; 2014 Jun; 49(6):411-20. PubMed ID: 24598440
[TBL] [Abstract][Full Text] [Related]
37. Detection of significant prostate cancer with magnetic resonance targeted biopsies--should transrectal ultrasound-magnetic resonance imaging fusion guided biopsies alone be a standard of care?
Delongchamps NB; Lefèvre A; Bouazza N; Beuvon F; Legman P; Cornud F
J Urol; 2015 Apr; 193(4):1198-204. PubMed ID: 25451824
[TBL] [Abstract][Full Text] [Related]
38. Diagnostic performance and reproducibility of T2w based and diffusion weighted imaging (DWI) based PI-RADSv2 lexicon descriptors for prostate MRI.
Benndorf M; Hahn F; Krönig M; Jilg CA; Krauss T; Langer M; Dovi-Akué P
Eur J Radiol; 2017 Aug; 93():9-15. PubMed ID: 28668436
[TBL] [Abstract][Full Text] [Related]
39. Evaluating the performance of PI-RADS v2 in the non-academic setting.
Jordan EJ; Fiske C; Zagoria RJ; Westphalen AC
Abdom Radiol (NY); 2017 Nov; 42(11):2725-2731. PubMed ID: 28451763
[TBL] [Abstract][Full Text] [Related]
40. Who can safely evade a magnetic resonance imaging fusion-targeted biopsy (MRIFTB) for prostate imaging reporting and data system (PI-RADS) 3 lesion?
Kim M; Ryu H; Lee HJ; Hwang SI; Choe G; Hong SK
World J Urol; 2021 May; 39(5):1463-1471. PubMed ID: 32696126
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
